KTRA Kintara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KTRA

Price (delayed)

$0.157

Market cap

$6.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.96

Enterprise value

$5.47M

Kintara Therapeutics, Inc. operates as a clinical and commercial stage drug development company with a focus on the treatment of cancer. The Company focuses on identifying clinical and commercial-stage compounds ...

Highlights
Kintara Therapeutics's EPS has soared by 58% YoY and by 24% from the previous quarter
The net income rose by 44% YoY and by 19% QoQ
Kintara Therapeutics's equity has plunged by 102% YoY but it has soared by 92% from the previous quarter
The quick ratio has plunged by 77% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kintara.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KTRA
Market
Shares outstanding
39.04M
Market cap
$6.13M
Enterprise value
$5.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$10.64M
EBITDA
-$10.58M
Free cash flow
-$6.79M
Per share
EPS
-$5.96
Free cash flow per share
-$1.57
Book value per share
-$0.05
Revenue per share
$0
TBVPS
$0.43
Balance sheet
Total assets
$1.89M
Total liabilities
$2.05M
Debt
$0
Equity
-$164,000
Working capital
-$684,000
Liquidity
Debt to equity
0
Current ratio
0.63
Quick ratio
0.35
Net debt/EBITDA
0.06
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-305.8%
Return on equity
-1,850.5%
Return on invested capital
N/A
Return on capital employed
-70,940%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KTRA stock price

How has the Kintara Therapeutics stock price performed over time
Intraday
-1.88%
1 week
4.67%
1 month
-4.27%
1 year
-96.4%
YTD
-7.43%
QTD
50.96%

Financial performance

How have Kintara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.63M
Net income
-$10.58M
Gross margin
N/A
Net margin
N/A
The net income rose by 44% YoY and by 19% QoQ
Kintara Therapeutics's operating income has increased by 44% YoY and by 19% QoQ

Growth

What is Kintara Therapeutics's growth rate over time

Valuation

What is Kintara Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kintara Therapeutics's EPS has soared by 58% YoY and by 24% from the previous quarter
Kintara Therapeutics's equity has plunged by 102% YoY but it has soared by 92% from the previous quarter

Efficiency

How efficient is Kintara Therapeutics business performance
KTRA's ROA has shrunk by 106% YoY and by 28% QoQ

Dividends

What is KTRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KTRA.

Financial health

How did Kintara Therapeutics financials performed over time
The total assets is 8% less than the total liabilities
The current ratio has surged by 174% since the previous quarter but it has dropped by 78% year-on-year
The total assets has plunged by 81% YoY but it has grown by 28% from the previous quarter
The debt is 100% greater than the equity
Kintara Therapeutics's equity has plunged by 102% YoY but it has soared by 92% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.